Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

FDA Tracks Critical Device Supply During Puerto Rico Hurricane Recovery

Continuing recovery efforts in Puerto Rico have US FDA focused on life-sustaining devices or those only made on the island. Meanwhile, manufacturers including Baxter, Zimmer, J&J and Abbott report varying impacts from the storms.

Medical Device Puerto Rico

Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK

There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.

Sales & Earnings Business Strategies

Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval

US FDA approved Yescarta without an advisory committee, as Novartis' first-in-class CAR-T cell therapy already set the stage for an agency review.

Approvals Regenerative Medicine

Scrip Asks… What's The Current Climate For Deal-Making? (Part 2)

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – featured here are big pharma and industry experts.

Business Strategies M & A
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register